Vis enkel innførsel

dc.contributor.authorStorm-Larsen, Christopheren_US
dc.contributor.authorMyhr, Kjell-Mortenen_US
dc.contributor.authorFarbu, Elisabethen_US
dc.contributor.authorMidgard, Runeen_US
dc.contributor.authorNyquist, Kaja Beateen_US
dc.contributor.authorBroch, Lineen_US
dc.contributor.authorBerg-Hansen, Pålen_US
dc.contributor.authorHov, Johannes Espolin Roksunden_US
dc.contributor.authorHolmøy, Trygveen_US
dc.PublishedStorm-Larsen C, Myhr KM, Farbu E, Midgard R, Nyquist KB, Broch L, Berg-Hansen PBH, Hov JR, Holmøy T. Gut microbiota composition during a 12-week intervention with delayed-release dimethyl fumarate in multiple sclerosis – a pilot trial. Multiple Sclerosis Journal, Experimental, Translational and Clinical. 2019;5(4)eng
dc.description.abstractIntroduction: Patients with multiple sclerosis may have a distinct gut microbiota profile. Delayed-release dimethyl fumarate is an orally administered drug for relapsing–remitting multiple sclerosis, which has been associated with gastrointestinal side-effects in some patients. Objectives: The purpose of this study was to determine if dimethyl fumarate alters the abundance and diversity of commensal gut bacteria, and if these changes are associated with gastrointestinal side-effects. Methods: Thirty-six patients with relapsing–remitting multiple sclerosis received either dimethyl fumarate (n = 27) or an injectable multiple sclerosis disease-modifying therapy (glatiramer acetate or interferons, n = 9) for 12 weeks. Stool samples were collected at baseline, two and 12 weeks. We included 165 healthy individuals as controls. Results: At baseline, 16 microbial genera were altered in multiple sclerosis patients compared with healthy controls. In the dimethyl fumarate-treated patients (n = 21) we observed a trend of reduced Actinobacteria (p = 0.03, QFDR = 0.24) at two weeks, mainly driven by Bifidobacterium (p = 0.06, QFDR = 0.69). At 12 weeks, we observed an increased abundance of Firmicutes (p = 0.02, QFDR = 0.09), mostly driven by Faecalibacterium (p = 0.01, QFDR = 0.48). Conclusions: This pilot study did not detect a major effect of dimethyl fumarate on the gut microbiota composition, but we observed a trend towards normalization of the low abundance of butyrate-producing Faecalibacterium after 12 weeks treatment. The study was underpowered to link microbiota to gastrointestinal symptoms.en_US
dc.rightsAttribution-Non Commercial CC BY-NCeng
dc.titleGut microbiota composition during a 12-week intervention with delayed-release dimethyl fumarate in multiple sclerosis – a pilot trialen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2019 The Authors
dc.source.journalMultiple Sclerosis Journal, Experimental, Translational and Clinical

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-Non Commercial CC BY-NC
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-Non Commercial CC BY-NC